http://money.cnn.com/news/newsfeeds/articles/marketwire/0319 425.htm
Mechelen, Belgium; 24 October 2007 - Galapagos NV (Euronext and LSE: GLPG) announced today that it has entered into a worldwide multi-target alliance with Janssen Pharmaceutica NV ('Janssen'), a Johnson & Johnson company, to discover and develop novel small-molecule therapeutics for the treatment of rheumatoid arthritis (RA). Under the alliance agreement, Janssen may select up to 12 programs from Galapagos' internally identified RA targets into the alliance. Janssen receives future option rights to exclusively license these programs. In addition, Janssen obtained an option to the future development and commercialization of product candidates from Galapagos' other internal RA programs, including its most advanced program based on the kinase target GT418. A compound from this proprietary drug discovery program is expected to enter Phase I clinical trials in 2008.